cll began report usd ep
prior period futur estim
adjust usd
cll began report usd revenu
prior period futur estim
adjust usd
anoth clinic pipelin project bag updat
pt
cellecti cll announc fda approv ind file
follow review period file earli may ind
cll third allogen off-the-shelf ucart candid acut b-cell
lymphoblast leukemia cll plan initi phase studi
incorpor model rais price target
previous remain bullish
ind r/r accept fda
phase studi initi led dr nitin jain prof hagop kantarjian
md anderson open-label dose-escalation/expans studi begin
cells/kg dose level respect
although initi phase studi target adult well-
known high-valu target believ potenti mani
hematolog malign cll also previous highlight
potenti target relaps patient re-dos treatment
updat model reflect cll financi statement file
also incorpor sale assum approv us
eu believ asid initi target
target approach also potenti dlbcl sll variou rare
cll complet offer april follow rais
subsidiari ownership last month cll
pro forma cash hand larg use build clinic
allogen manufactur capabl commerci infrastructur
manufactur
eha friday clls/allogene/servi present data
on-going phase studi pediatr adult pall
note due origin agreement june
cll limit abil pursu partnership june cll
potenti partner unencumb asset
cellecti develop biotechnolog
platform use talen gene edit
compani appli gene edit
creat allogen t-cell express
primari therapeut candid
target acut
myeloid leukemia aml cellecti
analyst certif import disclosur see disclosur
in-human data allogen off-the-shelf t-
cell immunotherapi ash/asgct technolog valid
preliminari posit result show valu cll gene-edit
technolog well-fund best-in-class car-t platform de-
risk cllss wholli own
asset cll partner allogen servier
collabor may yield mileston payment
cellecti also util gene-edit technolog develop
novel plant trait recent spun-out plant
phase interim data posit
data updat highlight efficaci respons similar
autolog car-t desir depth respons manag
enter clinic
cll file ind enter clinic earli
determin
initi phase studi
enter phase expans phase aml/
result rapid profound complet respons cr
rate aml and/or bpdcn lead earlier approv expect
program progress rapidli solid tumor demonstr
differenti cll technolog
cll appli gene-edit technolog car-t approach
demonstr profound single-ag remiss
highli competit larg multipl myeloma space
result graft-v -host diseas gvhd condit
make treatment suitabl critic ill patient
larg limit market opportun
demonstr unten side effect earli stage trial
aml/bpdcn addit clinic hold timelin delay
valu appli multipl estim world-wide sale aml discount annual
assum probabl market valu appli multipl estim ww sale
discount annual assum probabl market valu cash hand plu earli stage
pipelin valu royalty/mileston deal servier/allogen plant scienc
platform impli market cap
risk includ clinic regulatori commerci manufactur competit risk strateg risk financ risk liquid capit
risk risk currenc risk
annual result project usd thousand except per share data incom royalti revenu revenu total revenu expens royalti expens research develop sell gener administr oper incom expens total expens oper incom loss gain loss incom tax incom tax net incom loss non-control interest non expens sfa net incom attribut cellecti ep basic ep fulli dilult share outstand fulli dilut share outstand burn nol balanc cellecti sa
stock price compani mention report
